ArticleInfection and drug resistance2026
Efficacy and Safety of Contezolid as an Alternative to Linezolid for Treating MRSA Spinal Infections Following Linezolid-Induced Thrombocytopenia: A Single-Center Retrospective Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA)-associated spinal infections (SI) typically require prolonged antibiotic therapy. While linezolid (LZD) demonstrates efficacy against MRSA-SI, its clinical utility is often limited by the risk of thrombocytopenia. Contezolid (CZD), a novel oral oxazolidinone, potentially presents a lower risk of myelosuppression; however, clinical evidence supporting its use in SI remains limited. This retrospective study evaluated patients with MRSA-SI who transitioned to CZD (800 mg orally twice daily) after developing LZD-induced thrombocytopenia. Clinical outcomes, adverse events, and platelet recovery were assessed. All cases were identified from the Department of Infectious Diseases at the Second Affiliated Hospital of Naval Medical University. The study period was between November 2022 and April 2024, with a follow-up period of 8 to 24 weeks. Eight patients were included (median age 61 years; range 40-78). The median LZD treatment duration was 12 days (range 7-14), resulting in a decline in platelet counts from 125-300 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.